INTRODUCTION
The production of lipid mediators, the eicosanoids (i.e. prostaglandins and leukotrienes) are derived from metabolism of arachidonic acid, which has been implicated in the regulation of cell growth, inflammation, thrombosis and tumor progression (1) (2) (3) . There is much evidence indicating that eicosanoids, particularly prostaglandins, are involved in the etiologies of cancer (4) . Increased levels of eicosanoids occur in a number of different types of human cancer, including colon, pancreatic, breast and lung. In the case of lung cancer, increased prostaglandin biosynthesis has been found to occur mainly in non-small cell lung cancer (NSCLC), which comprises 80% of lung cancers rather than small cell lung cancer (SCLC) (5, 6) . In addition, the increase of cPLA 2 is correlated with the eicosanoid synthesis that participates in NSCLC transformation (7) .
Cytosolic phospholipase A 2 (cPLA 2 ) is the major intracellular form of PLA 2 , which preferentially hydrolyzes membrane phospholipids at the sn-2 position to release arachidonic acid (8) . cPLA 2 activity is regulated by intracellular Ca 2+ and phosphorylation. Increase in Ca 2+ results in translocation of cPLA 2 to the nuclear envelope and activation (9, 10) . But it has been shown that phorbol 12-myristate 13-acetate (PMA) provides cPLA 2 -activating signals without inducing Ca 2+ influx (11, 12) and by a Rac-p38 kinase-dependent pathway (13) . The maximal activation of cPLA 2 requires sustained phosphorylation of Ser505, Ser727 and Ser515 by mitogen-activated protein kinases (MAPKs), MAPK-activated protein kinases and by calcium/calmodulin-dependent protein kinase II, respectively (14) (15) (16) . In addition to acute regulation, expression of cPLA 2 through changes in gene transcription is mediated by a number of agents including cytokines, thrombin and growth factors (17) (18) (19) (20) (21) . The promoter for cPLA 2 has been isolated from both human (18) and rat (22) . A number of putative binding sites for possible regulatory elements have been identified within the promoter, including AP-1 sites, nuclear factor kB sites and glucocorticoid regulatory elements. Truncation of a 2.4 kb region of the promoter fragment down to the last 58 bp of the 5 0 -untranslated region has been identified in three regulatory regions and indicates that the transcription factor Sp1 can bind to two of these regions (23, 24) . In the regulation of cPLA 2 promoter, LKLF (lung Kru¨ppel-like factor) as a transcriptional activator also binds to the cPLA 2 promoter and may interact with the Sp1 family (25) .
Although Sp1 is required for the transcriptional activation of cPLA 2 gene, only a limited number of studies have addressed the mechanisms by which cPLA 2 gene expression is controlled. In addition to enzymatic activation, in this study, we also clarified that PMA could activate the transcription via the Sp1-binding sites of cPLA 2 a promoter in NSCLC A549 cells. We demonstrated that transcription factors c-Jun and Sp1 form a complex to regulate PMA-induced gene expression of cPLA 2 a as the manner as the c-Jun/Sp1-regulated genes including 12(S)-lipoxygenase, keratin 16, p21 WAF1/CIP1 and neuronal nicotinic acetylcholine receptor b4 (26) (27) (28) (29) . We further performed pull-down and protein-DNA interaction assays to show that nucleolin bound to DNA and activated transcription of cPLA 2 a in PMA-treated cells. Nucleolin is reported to be a ubiquitously expressed multifunctional protein involved in ribosomal biogenesis and the regulation of nucleolar translocation of ribosomal proteins (30) . Functional role of nucleolin in the activation and repression of gene transcription as well as in the regulation of RNA metabolism has already been reported (31) . Our results revealed a new function for nucleolin as a c-Jun/Sp1-interacting partner and transcription activator in PMA-induced gene expression of cPLA 2 a.
MATERIALS AND METHODS

Cell culture
Human epidermoid carcinoma A431 and NSCLC A549 cells were grown at 378C under 5% CO 2 in 10 cm plastic dishes containing 10 ml of Dulbecco's modified Eagle's medium (Invitrogen-GIBCO) and nutrition mixture F12 Kaighn's modification medium (Biowest), respectively and supplemented with 10% fetal bovine serum, 100 mg/ml streptomycin and 100 U/ml penicillin. In this series of experiments, cells were treated with 5 nM PMA (Sigma, St Louis, MO) in culture medium supplemented with 10% fetal bovine serum, unless stated otherwise.
Reverse transcription-PCR (RT-PCR)
Total RNA was isolated using the TRIzol RNA extraction kit (Invitrogen, Grand Island, NY), and 5 mg of RNA were subjected to RT-PCR with SuperScript TM II (Invitrogen, Grand Island, NY, USA). The cPLA 2 aspecific primers (sense, 5 0 -CTG ATG TTT GCA GAT TGG GTT G-3 0 ; antisense, 5 0 -AAA GGA GAC AGT GGA TAA GAT G-3 0 ), nucleolin-specific primers (sense, 5 0 -AGA AGG GAG CCA CAC CAG GC-3 0 ; antisense, 5 0 -AGC TGC TGC TTT CAT CGC TG-3 0 ) and GAPDH primers were used. The PCR products were separated by 1% agarose-gel electrophoresis and visualized with ethidium bromide staining.
Northern blot analysis
Total RNA was isolated using the TRIzol RNA extraction kit (Invitrogen, Grand Island, NY), and 20 mg of RNA were used for electrophoresis and transferred to a nylon membrane as previously described (32) . The cDNA probes used were prepared from RT-PCR. Probes were labeled with [a-32 P]dCTP by using a Rediprime TM II random prime labeling system (Amershan, Bucks, UK). The nylon membranes were washed three times at room temperature in 2Â standard saline/phosphate/EDTA buffer (300 mM NaCl, 20 mM NaH 2 PO 4 and 2 mM EDTA) containing 0.1% SDS. Each wash was carried out for 15 min. Autoradiography was then performed.
Plasmid construction
A 619 bp of human cPLA 2 a promoter region was PCRamplified from human genomic DNA and subcloned into luciferase plasmid pXP1 as the pPLA599 plasmid. Respective additions of KpnI to forward primer 5 0 -GA AATTCAAACCTGAATTCAATTTTCTTCCCT-3 0 and of HindIII to reverse primer 5 0 -GATCCTTTTTCAGC TCCGGA-3 0 facilitated subcloning. 5 0 -Deletions of various lengths, pPLA393, pPLA241, pPLA140, pPLA53, pPLA35 and pPLA27 were generated using reverse primer 5 0 -GATCCTTTTTCAGCTCCGGA-3 0 and the forward primers
0 , 5 0 -TAGCCCCTCCTACTCAGG-3 0 and 5 0 -CCTACTCAGGATAAGACT-3 0 , respectively. The mutants at Sp1 site (pLAm) were constructed by the site-directed mutagenesis method. Synthetic primers were shown in the following: pLAm1 mutant primer 5 0 -GG AGACCAGTTCACATTTTAG -3 0 , and pLAm2 mutant primer 5 0 -TAGTTCTTCCTACTCAGG -3 0 . Mutated positions in the sequence of the primers were underlined. All DNA fragments were directly subcloned into pXP1 using KpnI and HindIII. The vector sequence was confirmed by DNA sequencing. To generate the luciferase plasmid UTR-1-446, a 447 bp of human cPLA 2 a mRNA 3 0 UTR was PCR-amplified from cDNA and inserted between luciferase gene and SV40 late poly(A) signal coding regions of luciferase plasmid pGL3. Respective additions of XbaI to forward primer 5 0 -TTCATG TACTGGAAATGGCAGC-3 0 and of FseI to reverse primer 5 0 -CATGTATGTATATATATGC-3 0 facilitated subcloning. The nucleotide sequences of constructs were confirmed by automatic DNA sequencing.
Transfection of cells with plasmids
Cells were transfected with plasmids by lipofection using Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instruction with a slight modification. Cells were replated 24 h before transfection at an optimal cell density in 2 ml of fresh culture medium in a 3.5 cm plastic dish. For use in transfection, 0.5 ml of Lipofectamine 2000 was incubated with 0.5 mg of pPLA, pXLO-7-1 of human 12(S)-lipoxygenase (33) or pXC918 of cyclooxygenase-2 (34) luciferase plasmid or the indicated plasmids as described in each experiment, in 1 ml of Opti-MEM medium for 30 min at room temperature. Total DNA concentration for each transfection was normalized with pcDNA3.1. Cells were transfected by changing the medium with 1 ml of Opti-MEM medium containing the plasmids and Lipofectamine 2000, followed by incubation at 378C in a humidified atmosphere of 5% CO 2 for 24 h. After a change of Opti-MEM medium to 2 ml of fresh culture medium, cells were stimulated with PMA if necessary and then incubated for an additional 18 h, unless stated otherwise. The luciferase activity in cell lysate was determined as described previously (33) .
DNA affinity precipitation assay (DAPA)
This assay was performed according to the method reported previously (35) 0 , respectively, and 20 ml of streptavidin-agarose beads (4%) with 50% slurry. Mutated positions in the sequence were underlined. The mixture was incubated at room temperature for 1 h with rotating. Beads were pelleted and washed three times with PBS. The binding proteins were eluted by loading buffer and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by western blot analysis probed with specific antibodies.
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation assay was done according to previous report (36) with minor modification. Briefly, A549 cells were treated with 1% formaldehyde for 15 min. The cross-linked chromatin was sonicated to 400-500 bp fragments. Lysates were precleared with protein A beads and incubated overnight at 48C with antibodies specific to nucleolin (Santa Cruz Biotechology, Santa Cruz, CA, USA), c-Jun (Santa Cruz, CA, USA) and Sp1 (Santa Cruz, CA, USA). Immune complex was precipitated with protein A beads preabsorbed with sonicated salmon sperm DNA and BSA. After reversal of cross-linking, levels of precipitated cPLA 2 a promoter DNA were determined by PCR using oligonucleotides spanning the Sp1-binding sites (sense, 5 0 -ACA GAA ATC CGC AAC AGC ACT C-3 0 ; antisense, 5 0 -GAT CCT TTT TCA GCT CCG GA-3 0 ). The PCR products were separated by 1% agarose-gel electrophoresis and visualized with ethidium bromide staining.
Western blotting
The cytoplasmic fractions and nuclear extracts of cells were prepared for western blot analysis according to the method described (37) . An analytical 10% SDS-PAGE was performed, and 30 mg of protein of each sample were analyzed, unless stated otherwise. For immunoblotting, proteins in the SDS gels were transferred to a polyvinylidene difluoride membrane by an electroblot apparatus. Antibodies against human Sp1 (Santa Cruz, CA, USA), c-Jun (Santa Cruz, CA, USA), nucleolin (Santa Cruz, CA, USA) and b-actin (Santa Cruz, CA, USA) were used as the primary antibodies. Mouse or rabbit IgG antibodies coupled to horseradish peroxidase were used as secondary antibodies. An enhanced chemiluminescence kit (Pierce, Rockford, IL, USA) was used for detection.
Coimmunoprecipitation
Two hundred micrograms protein of nuclear extracts and lysate were incubated under gentle shaking at 48C overnight with a mixture of anti-c-Jun or anti-Sp1 antibodies and protein A agarose in 300 ml of immunoprecipitation buffer [20 mM HEPES, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 and 25% glycerol (v/v), 0.5 mM phenylmethylsulfonyl fluoride, 1 mM orthovanadate, 2 mg/ml pepstatin A and 2 mg/ml leupeptin]. Beads were pelleted at 7500g for 2 min and washed three times with RIPA buffer [50 mM Tris-HCl, pH 7.5, 1% IGEPAL CA-630 (v/v), 150 mM NaCl, and 0.5% sodium deoxycholate]. Protein was removed from the beads by boiling in sample buffer (120 mM Tris-HCl, pH 6.8, 10% glycerol, 3% SDS, 20 mM DTT, and 0.4% bromophenol blue) for 5 min and subjected to 10% SDS-PAGE. Western blot analysis was carried out as described above.
RESULTS
Effect of PMA on the transcription of cPLA 2 a gene Expression of cPLA 2 a was detected by northern blot and immunoblot analysis in PMA-treated A549 cells. PMA induced the expression of cPLA 2 a mRNA ( Figure 1A ) and protein ( Figure 1B ) in a time-dependent manner. To confirm that PMA enhanced the expression of cPLA 2 a through the transcriptional activation of the gene, the vector containing human cPLA 2 a gene promoter was used in the reporter assay. PMA induced the promoter activity of cPLA 2 a in a time-dependent manner ( Figure 2A ). The maximum effect of PMA on the promoter activity was observed in cells treated with PMA for 18 h. To identify the promoter elements responsible for PMA induction, DNA constructs with 5 0 -deletions of cPLA 2 a promoter were transiently transfected into cells. The effect of PMA on the luciferase reporter activity was then studied and summarized in Figure 2B . The luciferase activities of vectors pPLA 599, pPLA 393, pPLA 241, pPLA 140 and pPLA 53 were stimulated by PMA treatment. The stimulation was about 5-fold, obtained by comparing the luciferase activity in PMA-treated cells with that in control cells. An apparent decrease in the stimulatory response of PMA was observed in vectors bearing a promoter with a deletion from À53 (pPLA 53) to À27 bp (pPLA 27), indicating that a promoter region ranging from À53 to À27 bp was required for the PMA-induced expression of cPLA 2 a. To further confirm whether two Sp1-binding sites (À45 to À42 bp and À33 to À29 bp) located in the region were important for PMA response, DNA constructs with mutations on Sp1-binding sites were transfected into cells. Compared to pPLA599, a significant decrease in PMA-stimulated response was observed in pPLA m1 and pPLA m2, and a complete elimination of PMA response was detected in pPLA m1/2. In addition, overexpression of Sp1 also induced the promoter activity of cPLA 2 a ( Figure 2C ). These results indicated that two Sp1 sites were essential for PMA-induced transcriptional activation of cPLA 2 a gene and Sp1 was involved in the regulation of gene expression.
Effect of c-Jun/Sp1 on the PMA-induced transcriptional activation of cPLA 2 a gene Since overexpressing Ha-Ras leads to induction of c-Jun protein and drives rat cPLA 2 a promoter activity (23), we then studied the possibility that whether c-Jun also cooperated with Sp1 in the regulation of PMA-induced expression of human cPLA 2 a gene. To confirm the role of c-Jun in PMA-regulated gene expression, c-Jun siRNA oligonucleotides were transfected into cells. As shown in Figure 3A , c-Jun siRNA inhibited PMA-induced promoter activity and protein expression of cPLA 2 a. Furthermore, overexpression of c-Jun also induced the promoter activity of cPLA 2 a gene ( Figure 3B ). Consistent with the results of Figure 2B , the luciferase activity of vectors pPLA 599, pPLA 393, pPLA 241, pPLA 140 and pPLA 53 but not pPLA 35 and pPLA 27 were stimulated by pRSVjun ( Figure 3B) . A significant decrease in pRSVjun response was observed in pPLA m1 and pPLA m2, whereas the response was completely abolished in pPLA m1/2. These results indicated that the two Sp1 sites play an important role in c-Jun-induced transcription of cPLA 2 a gene as well as the PMA response ( Figure 2B ). Since there is no AP1 site within the promoter region ranging from À53 to À27 bp, we therefore speculated that the effect of c-Jun on gene expression was mediated by cooperation with Sp1.
We then studied the functional interaction between c-Jun and Sp1 in the regulation of PMA-induced gene expression of cPLA 2 a by immunoprecipitation, DAPA and ChIP assay. Expression of Sp1 and c-Jun in nuclear extracts prepared from cells treated with PMA for 1-6 h was studied by using immunoblot analysis. No difference of Sp1 expression between control and PMA-treated cells was observed ( Figure 4A ). PMA induced the expression of c-Jun ( Figure 4A) , and enhanced the interaction between c-Jun and Sp1 ( Figure 4B ). To directly examine whether the c-Jun/Sp1 complex bound to cPLA 2 a promoter in PMA-treated cells, the probes containing two Sp1-binding sites of cPLA 2 a promoter were used in DAPA. The binding of c-Jun and phospho-c-Jun but not Sp1 to the promoter under the PMA stimulation was increased ( Figure 4D and E). In addition, phospho-c-Jun binding to the promoter was significantly increased by overexpressed Sp1 in cells ( Figure 2C ). In ChIP assay, the binding of c-Jun but not Sp1 to the promoter in cells under the PMA treatment was also enhanced ( Figure 4F ). These results suggested that PMA induced the formation of c-Jun/Sp1 complex, resulting in facilitating the access of activated c-Jun to the promoter and enhanced the transcriptional activation.
Nucleolin mediates the PMA-induced transcriptional activation of cPLA 2 a gene To gain insight into the PMA-regulated transcriptional mechanism of cPLA 2 a gene, factors bound to Sp1 sties of cPLA 2 a promoter were analyzed by DAPA. The bound proteins were subsequently analyzed by 2D SDS-PAGE. Proteins on the gel were identified by MALDI-TOF. One of the proteins, nucleolin bound to the probe was then clearly identified (data not shown). As shown in Figure 4D analyzed by DAPA, the binding of nucleolin to the promoter was not changed in PMA-treated cells as well as Sp1 binding. In addition, the constant interaction between nucelolin and Sp1 was observed in control or PMAtreated cells ( Figure 4C ). However, the interaction of nucleolin with c-Jun was increased in PMA-treated condition ( Figure 4C ). We further confirmed the binding of nucleolin to cPLA 2 a promoter by ChIP assay ( Figure 4F ), which was consistent with the results shown in Figure 4D . Since the formation and binding of c-Jun/ nucleolin complex to cPLA 2 a promoter was increased in PMA-treated cells, it is likely that nucleolin is involved in the regulation of PMA-induced cPLA 2 a gene expression. We then studied the role of nucleolin in the regulation of PMA-induced gene expression. As shown in Figure 5A , PMA-induced promoter activity and protein expression of cPLA 2 a were inhibited in nucleolin knockdown cells. Nucleolin siRNA oligonucleotides also significantly inhibited the PMA-induced increase of cPLA 2 a mRNA ( Figure 5B ). These results revealed that c-Jun/nucleolin complex played an important role in PMA-induced program 'TFSEARCH' and interpreted AP1, Sp1 and C/EBP a/b binding sites on the promoter region ( Figure 6A ). No change of luciferase activity was observed in nucleolin knockdown cells ( Figure 6C ), indicating that nucleolin had no effect on the SV40 promoter activity and mRNA stability of the luciferase gene. The expression of luciferase gene was inhibited in c-Jun siRNA oligonucleotides-transfected cells ( Figure 6C ). Since nucleolin had no effect on the mRNA stability of luciferase gene, together with the reporter assay from Figure 5A , these results indicated that nucleolin was involved in the PMA-induced transcriptional activation of cPLA 2 a gene. To further study whether nucleolin could also play a function in post-transcriptional activation, we used UTR-1-446 vector, containing SV40 promoter and luciferase cDNA followed by cPLA 2 a 3 0 UTR sequence ( Figure 6B ) to dissect the requirement of 3 0 UTR sequence responsible for nucleolin-regulated mRNA stability. As shown in Figure 6D , nucleolin siRNA significantly reduced luciferase activity, indicating nucleolin was involved in the regulation of cPLA 2 a mRNA stability. In addition, PMA had no effect on UTR-1-446 luciferase activity ( Figure 6D ), indicating that cPLA 2 a 3 0 UTR sequence was not essential for PMA-regulated cPLA 2 a gene expression. These results revealed that PMA regulated cPLA 2 a expression by favoring transcriptional activation pathway but not through mRNA stabilization. However, nucleolin contributed to not only PMAinduced transcriptional activation of cPLA 2 a gene but also stabilization of cPLA 2 a mRNA in cells without PMA treatment.
Nucleolin and Sp1 are individually essential for the recruitment of c-Jun to GC-rich promoter
Several lines of evidence reveal that the motif (U/G)CCCG(A/G) is important for nucleolin RNA binding (39) . However, it is interesting to note that cPLA 2 a promoter, containing two potential Sp1-binding sequences, AGCCCA and AGCCCCT might also be considered as the nucleolin recognition element. We then clarified whether the binding of nucleolin to cPLA 2 a promoter was Sp1-dependent. In Sp1 knockdown cells ( Figure 7A ), the amount of c-Jun on DNA was reduced to 50% ( Figure 7B ). However, Sp1 siRNA had no significant effect on the binding of nucleolin to DNA. We further studied whether nucleolin was required for Sp1-DNA interaction. Although the interaction of Sp1 with DNA was not changed in nucleolin siRNA-treated cells, the binding of c-Jun to DNA was almost abolished ( Figure 7B ). To clarify that whether nucleolin bound to DNA through Sp1-binding sites, we studied the binding of nucleolin to wild-type Sp1 probes, compared to mutated probes. As shown in Figure 7C , mutated Sp1 probes abolished both bindings of Sp1 and nucleolin to DNA, resulting in complete inhibition of the interaction between c-Jun and DNA. These results indicated that the bindings of nucleolin and Sp1 to DNA were independent of each other. Furthermore, in addition to Sp1, nucleolin might also be an anchor protein to recruit c-Jun to Sp1 sites and activated cPLA 2 a gene expression in PMA-treated cells. In order to further dissect that whether the binding of nucleolin to Sp1 site was mediated by recognizing the canonical or non-canonical Sp1 sequence, the promoters with consensus Sp1 sequence of 12(S)-lipoxygenase (33) and gastrin (40) or consensus Sp1 oligonucelotides were used in DAPA. Although the binding of Sp1 to Sp1-binding site was observed as expectations, the interaction between nucleolin and DNA was only observed in cPLA 2 a promoter, 12(S)-lipoxygenase promoter and consensus Sp1 oligonucleotide. However, no interaction between nucleolin and DNA was observed in gastrin promoter or consensus NFkB site ( Figure 7D ). The binding of phospho-c-Jun to DNA was increased in all oligonucleotide probes in PMA-treated cells ( Figure 7D ). These results revealed that not all the Sp1 or Sp1-like binding sites were in favor of nucleolin binding, indicating that the binding of nucleolin to Sp1 site was not determined by canonical or non-canonical Sp1-binding sequence. To further confirm that nucleolin was essential for c-Jun/Sp1-regulated gene expression resulted from the recruitment of c-Jun to Sp1 sites-dependent transcriptional activation, we studied the effect of nucleolin on the induction of 12(S)-lipoxygenase which is Sp1-dependent, and cyclooxygenase-2 which is Sp1-independent in cells under EGF treatment (33, 34) . Under these experimental conditions, c-Jun is essential for the EGF-induced expression of 12(S)-lipoxygenase and cyclooxygenase-2. Consistent with that observed in the regulation of cPLA 2 a gene, nucleolin siRNA abolished the EGF-induced transcriptional activation of 12(S)-lipoxygenase gene ( Figure 8A ). Contrary to c-Jun/Sp1-regulated genes, nucleolin was not involved in EGF-induced transcriptional activation of cyclooxygenase-2 gene (Figure 8B ).
DISCUSSION
The expression of cPLA 2 can be regulated in NSCLC (7) and is critical for transformed growth of NSCLC. When these cells are treated with a specific inhibitor of the enzyme, or blocking downstream production of prostaglandins with cyclooxygenase inhibitors, resulting in inhibition of anchorage-independent growth of these cells (7) . These results suggest that induction of cPLA 2 is critical for tumorigenesis. Consistent with this finding, lung tumorigenesis is inhibited in mice that are deficient in cPLA 2 (41) . In this study, we first found that PMA induced gene expression of cPLA 2 a in NSCLC. It has been known that PMA-activated PKC signal transduction pathway is thought to be involved in the oncogene G T T C A T G T A C T G G A A A T G G C A G C A G T T T C T G A T  + 3 3 G C T G A G G C A G T T T G C A A T C C C A T G A C A A C T G G A T T T A A A A  + 7 3 G T A C A G T A C A G A T A G T C G T A C T G A T C A T G A G A G A C T G G C T  + 1 1 3 G A T A C T C A A A G T action in NSCLC and enzymatic activation of cPLA 2 . Activation of PKC with PMA impairs progression of lung adenocarcinoma cells from early G1 phase into S phase (42) . The broad-range PKC inhibitor staurosporine analog, PKC 412, induces apoptosis in SCLC cells and sensitizes NSCLC cells to apoptosis induced by DNAdamaging agents (43) . Taking these results together, we concluded that PMA-induced expression of cPLA2a might be related to either a cause or a consequence of PMA-regulated tumorigenesis of NSCLC.
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In the regulation of gene expression, previous studies have reported that c-Jun/Sp1 complex is critical for various different gene expressions, e.g. 12(S)-lipoxygenase, keratin 16, p21 WAF1/CIP1 and neuronal nicotinic acetylcholine receptor b4 (26) (27) (28) (29) . Although overexpression of c-Jun and Sp1 produces a synergistic increase in the rat cPLA 2 promoter activity, no evidence shows that the formation of c-Jun/Sp1 complex and the complex binding to the rat cPLA2 promoter are observed (23) . However, we first clarified that PMA induced c-Jun/Sp1 interaction and the complex bound to Sp1-binding sites of human cPLA2a promoter, resulting in the induction of transcriptional activation. In addition, we found that nucleolin was also a coactivator interacting with c-Jun to regulate PMAinduced transcription of cPLA 2 a gene. Nucleolin is a ubiquitous, nonhistone nucleolar phosphoprotein of exponentially growing eukaryotic cells, which is directly involved in the regulation of ribosome biogenesis, the processing of ribosomal RNA, mRNA stability, transcriptional regulation and cell proliferation, and it is also a downstream target of several signal transduction pathways (30) . Matching our results, the functional role of nucleolin involved in the transcriptional activation of gene expression has been found. Nucleolin binds acetylated interferon regulatory factor-2 (IRF-2) to enhance H4 promoter activity (44) and plays as a key activator of HPV18 oncogene transcription in cervical cancer (45) . Nucleolin also binds transcription factors Myb and tumor suppressor Rb to regulate Myb transcriptional activity and tumor development (46, 47) . These findings suggest that nucleolin may act as a transcriptional regulator via interacting with activators. Indeed, in the experiments of immunoprecipitation and DAPA, we found that nucleolin bound and bridged c-Jun to Sp1-binding sites of cPLA 2 a promoter ( Figures 4C and 7B) . These results suggested the possibility that nucleolin participated in the regulation of c-Jun/Sp1-regulated genes, e.g. 12(S)-lipoxygenase ( Figure 7D ) and p21 WAF1/CIP1 to regulate cell growth (48) . From our study, we can conclude that for PMAinduced cPLA 2 a gene expression, and nucleolin acts as a coactivator via cooperation of c-Jun transcriptional factor. However, the nucleolin/c-Jun complex had no effect on AP1-regulated promoter activation ( Figures 6C  and 8B ). The different binding affinity between nucleolin/ c-Jun to Sp1-binding site and to AP1-binding site might be caused by the stereo-recognition of complex to the Sp1 binding but not AP1-binding sequences. Consistent with the role of nucleolin in the regulation of mRNA stability, we found that nucleolin also contributed to the stabilization of cPLA 2 a mRNA. Since without identical nucleolinbinding site UCCCGA but with HuR-binding element AUUUA is found within the cPLA 2 a 3 0 UTR sequence, the effect of nucleolin on the stabilization of cPLA 2 a mRNA might result from the cooperation of nucleolin with RNA-binding proteins as well as the basal expression of GADD45a mRNA is regulated by association of nucleolin and HuR (49) . Indeed, we found that RNAbinding protein HuR bound to AUUUA of cPLA 2 a 3 0 UTR sequence and enhanced the mRNA stability (our unpublished data). Although PMA had no effect on the stabilization of cPLA 2 a mRNA, our data showed that nucleolin was also involved in the regulation of PMAinduced transcriptional activation of cPLA 2 a gene. These results revealed that nucleolin plays dual functions of transcriptional and post-transcriptional activity in the regulation of cPLA 2 a gene.
It is known that the motif (U/G)CCCG(A/G) is responsible for the binding of nucleolin to RNA (39) . However, we found that the binding of nucleolin to the GC-rich Sp1 site within cPLA 2 a promoter was in an Sp1-independent manner. Thus, nucleolin might gain access to DNA through two pathways. First, since Sp1 siRNA had no effect on the binding of nucleolin to Sp1 element, indicating that nucleolin might directly bind to DNA and recruit c-Jun transcriptional factor to Sp1 sites and then activate gene expression. Nucleolin is a matrix attachment region (MAR)-binding protein to provide a link between DNA and nuclear matrix scaffolding (50) . In addition, nucleolin was also found to bind to the NFkB DNAbinding motif and the KLF2 promoter (51, 52) . Thus, nucleolin may interact with DNA and other transcriptional factors, such as c-Jun, to regulate transcription. It is very interesting to note that whether the binding of nucleolin to GC-rich Sp1 site has the sequence specificity. Contrary to the binding of nucleolin to cPLA 2 a promoter, we found that SV40 promoter containing Sp1-binding sites was not regulated by nucleolin. Furthermore, we also found that the interaction between nucleolin and Sp1-binding site was not occurred in all Sp1-regulated promoters such as gastrin. It is possible that the nucleotide sequence surrounding the AGCCC and UCCCGA can modulate the interaction of nucleolin with DNA and RNA (39), respectively. Second, access of nucleolin to cPLA 2 a promoter may also skip from direct binding but be bridged by other factors to DNA. Although there was no effect of Sp1 siRNA on nucleolin binding, we could not rule out the possibility that the binding of nucleolin to DNA might have occurred concomitant with Sp1-like proteins binding. In addition, in spite of nucleolin and Sp1 bound to DNA was dependent on Sp1-binding sites, the binding of Sp1 to DNA was in a nucleolin-independent manner. These results suggested that Sp1/c-Jun and nucleolin/c-Jun complexes could together or independently bind to Sp1-binding sites and regulate PMAinduced transcriptional activation of cPLA 2 a gene.
In conclusion, we have identified the functional interaction between c-Jun, nucleolin and Sp1 to mediate cPLA 2 a expression in PMA signal-activated human tumor cells. Our results demonstrate that the activation of the PMA signaling pathway leads to the binding of c-Jun/ nucleolin and c-Jun/Sp1 complexes to the cPLA 2 a promoter, resulting in the transcriptional activation of cPLA 2 a gene. Based on the expression of cPLA 2 a is critical for transformed growth of NSCLC and tumorigenesis (7, 41) , our study suggested that nucleolin, in addition to contribute to the process of tumor development by linking to major tumor suppressors, Rb and p53 (47, 53) , could associate with transcription factor c-Jun and up-regulate cPLA 2 a expression to increase lipid mediators, resulting in the tumorigenesis. Our data also suggested that nucleolin binds to GC-rich elements. It is likely that nucleolin binding at place of Sp1-binding sequences could also mediate the expression of c-Jun/Sp1-activated genes.
